IDEXX Laboratories is a healthcare company with a market cap of $53.6 billion, specializing in diagnostics for animals and water quality analysis. Analysts predict a Q4 profit of $2.93 per share, exceeding Wall Street estimates for the fourth consecutive quarter.

For fiscal 2025, IDXX is expected to report an EPS of $12.93, a 21.2% increase from the previous year. Analysts anticipate further growth to $14.42 in fiscal 2026.

IDXX shares have surged 61.4% in the past year, outperforming major indices like the S&P 500. Strong financial results and demand for diagnostic products drove the stock’s rise.

Wall Street analysts rate IDXX as a “Moderate Buy,” with a mean price target of $790.67, suggesting an 18% potential upside from current levels. Analysts are optimistic about the company’s future growth.

Read more at Yahoo Finance: What to Expect From IDEXX Laboratories’ Next Quarterly Earnings Report?